In 2012, a study was published titled “Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study.” that aimed to evaluate the connection between the thiazolidinedione class of diabetes drugs (e.g. Actos) and bladder cancer. The study appeared in Journal of the National Cancer Institute and was prepared by R. Mamtani et al.
As such, the study team writes, “The use of pioglitazone, a thiazolidinedione (TZD), may increase the risk of bladder cancer in patients with type 2 diabetes. In this study, we assessed the risk of bladder cancer associated with the use of TZDs and between pioglitazone and rosiglitazone, an alternative TZD.”
This team studied people who used TZDs (18,459) and compared health outcomes with patients who used sulfonylurea (41,396) in the treatment of type-II diabetes. Describing results, the team states “We identified 60 incident bladder cancers in the TZD cohort and 137 cancers in the SU cohort” and “the risk of bladder cancer was increased among patients with the longest duration of TZD vs SU therapy”. That is, bladder cancer was identified among both groups, but that long duration TZD use gave more bladder cancer than SU. “Risk of bladder cancer also increased with increasing time since initiation of [Actos] and [Avandia]”.
Due to the act that many people used Actos unaware of the risk for bladder cancer associated, a number of Actos bladder cancer lawsuits have been filed. If you or a loved one used Actos and suffered bladder cancer, you too may be entitled to significant financial compensation. For a free, no-obligation case consultation, contact our team of Actos bladder cancer lawyers at the information provided below. We have the compassion, resources, and experience required to win the justice you deserve.
Call today and see how we can help.
(855) 452 – 5529